07/24/2026
https://www.biospace.com/press-releases/alembic-therapeutics-llc-announces-the-launch-of-pivya-pivmecillinam
Alembic Therapeutics acquired the rights to Pivya (Pivmecillinam) for treatment of uncomplicated UTI's in the United States. Now available.
BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S. availability of Pivya® (pivmecillinam) tablets, 185mg, an oral prescription antibiotic. Pivya contains pivmecillinam, a beta-lactam antibacterial agent with a long history of use internationally...